HC Wainwright Reiterates “$5.00” Price Target for BioDelivery Sciences International, Inc. (BDSI)

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has been assigned a $5.00 price target by analysts at HC Wainwright in a report released on Friday. The firm currently has a “buy” rating on the specialty pharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 70.94% from the stock’s previous close.

A number of other research analysts have also commented on BDSI. Piper Jaffray Companies set a $4.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research note on Wednesday, August 9th. Cantor Fitzgerald set a $5.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research note on Thursday. Roth Capital set a $5.00 price objective on shares of BioDelivery Sciences International and gave the company a “buy” rating in a research note on Thursday. ValuEngine lowered shares of BioDelivery Sciences International from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. Finally, Zacks Investment Research upgraded shares of BioDelivery Sciences International from a “hold” rating to a “buy” rating and set a $3.00 price objective on the stock in a research note on Wednesday, July 12th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $4.29.

BioDelivery Sciences International (NASDAQ:BDSI) last posted its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The business had revenue of $8.70 million during the quarter, compared to analyst estimates of $8.45 million. BioDelivery Sciences International had a net margin of 3.34% and a return on equity of 14.64%. The company’s revenue for the quarter was up 74.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.31) earnings per share.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thestockobserver.com/2017/10/13/hc-wainwright-reiterates-5-00-price-target-for-biodelivery-sciences-international-inc-bdsi.html.

In other news, CEO Mark A. Sirgo sold 54,833 shares of the business’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $2.90, for a total transaction of $159,015.70. Following the transaction, the chief executive officer now directly owns 1,509,262 shares in the company, valued at $4,376,859.80. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Mark A. Sirgo sold 50,000 shares of the business’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $2.95, for a total transaction of $147,500.00. Following the transaction, the chief executive officer now owns 1,509,262 shares in the company, valued at $4,452,322.90. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 402,127 shares of company stock worth $1,142,798. Company insiders own 9.00% of the company’s stock.

Institutional investors have recently modified their holdings of the company. Valley National Advisers Inc. increased its stake in shares of BioDelivery Sciences International by 59.0% during the second quarter. Valley National Advisers Inc. now owns 37,715 shares of the specialty pharmaceutical company’s stock worth $106,000 after acquiring an additional 14,000 shares during the period. Stonepine Capital Management LLC increased its stake in shares of BioDelivery Sciences International by 22.2% during the second quarter. Stonepine Capital Management LLC now owns 3,477,673 shares of the specialty pharmaceutical company’s stock worth $9,737,000 after acquiring an additional 632,853 shares during the period. KCG Holdings Inc. increased its stake in shares of BioDelivery Sciences International by 469.9% during the first quarter. KCG Holdings Inc. now owns 110,728 shares of the specialty pharmaceutical company’s stock worth $210,000 after acquiring an additional 91,297 shares during the period. Grandeur Peak Global Advisors LLC increased its stake in shares of BioDelivery Sciences International by 5.9% during the first quarter. Grandeur Peak Global Advisors LLC now owns 1,007,006 shares of the specialty pharmaceutical company’s stock worth $1,913,000 after acquiring an additional 56,550 shares during the period. Finally, GSA Capital Partners LLP increased its stake in shares of BioDelivery Sciences International by 10.1% during the second quarter. GSA Capital Partners LLP now owns 488,767 shares of the specialty pharmaceutical company’s stock worth $1,369,000 after acquiring an additional 44,700 shares during the period. Institutional investors and hedge funds own 41.43% of the company’s stock.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply